Univariate analysis of survival outcome
| Variable | N | Events | 5-Year PFS (95% CI) | Hazard ratio (95% CI) | P value | Events | 5-Year OS (95% CI) | Hazard ratio (95% CI) | P value |
| Adjuvant treatment | |||||||||
| Adjuvant therapy | 304 | 56 (18%) | 77.2 (71.4 to 82.9) | 0.55 (0.35 to 0.87) | 0.011 | 52 (17%) | 81.5 (76.2 to 86.8) | 0.42 (0.28 to 0.65) | <0.001 |
| OBS | 101 | 27 (27%) | 69.6 (59.4 to 79.9) | -- | 36 (36%) | 60.2 (48.9 to 71.6) | -- | ||
| Treatment | |||||||||
| OBS | 101 | 27 (27%) | 69.6 (59.4 to 79.9) | -- | 36 (36%) | 60.2 (48.9 to 71.6) | -- | ||
| EBRT | 46 | 9 (20%) | 73.0 (55.4 to 90.6) | 0.64 (0.30 to 1.37) | 0.25 | 9 (20%) | 73.9 (57.3 to 90.5) | 0.58 (0.28 to 1.22) | 0.15 |
| VBT | 138 | 22 (16%) | 81.0 (73.4 to 88.5) | 0.48 (0.27 to 0.84) | 0.010 | 21 (15%) | 82.9 (75.8 to 90.1) | 0.38 (0.22 to 0.65) | <0.001 |
| VBT+C | 58 | 10 (17%) | 78.8 (66.8 to 90.8) | 0.47 (0.23 to 0.96) | 0.039 | 9 (16%) | 82.7 (71.6 to 93.8) | 0.33 (0.16 to 0.70) | 0.003 |
| EBRT+VBT | 21 | 7 (33%) | 60.3 (33.5 to 87.1) | 1.05 (0.46 to 2.42) | 0.91 | 6 (29%) | 73.9 (51.1 to 96.7) | 0.68 (0.29 to 1.61) | 0.38 |
| Chemo | 8 | 2 (25%) | 65.6 (24.7 to 100.0) | 0.75 (0.18 to 3.15) | 0.69 | 2 (25%) | 66.7 (13.3 to 100.0) | 0.67 (0.16 to 2.78) | 0.58 |
| EBRT+C | 16 | 2 (13%) | 85.7 (67.4 to 100.0) | 0.37(0.09 to 1.56) | 0.18 | 3 (19%) | 87.1 (70.3 to 100.0) | 0.46 (0.14 to 1.50) | 0.20 |
| EBRT+VBT+C | 14 | 2 (14%) | 80.8 (56.8 to 100.0) | 0.38 (0.09 to 1.60) | 0.19 | 1 (7%) | 100.0 (100.0 to 100.0) | 0.16(0.02 to 1.14) | 0.067 |
| Hormonal only | 3 | 2 (67%) | 0 | 4.45 (1.05 to 18.82) | 1 (33%) | 100.0 (100.0 to 100.0) | 1.12 (0.15 to 8.20) | ||
| Myometrial invasion | 155 | 37 (24%) | 70.3 (61.7 to 78.9) | 1.589 (1.006 to 2.509) | 0.047 | 40 (26%) | 68.7 (59.5 to 77.9) | 1.73 (1.10 to 2.73) | 0.019 |
| Grade 2 or 3 | 344 | 74 (22%) | 74.5 (69.2 to 79.9) | 1.44 (0.72 to 2.87) | 0.31 | 79 (23%) | 74.6 (69.1 to 80.1) | 1.55 (0.78 to 3.09) | 0.21 |
| Stage | |||||||||
| IA | 140 | 22 (16%) | 82.0 (74.8 to 89.2) | -- | 19 (14%) | 86.3 (79.7 to 92.9) | -- | ||
| IB | 216 | 46 (21%) | 73.8 (66.6 to 80.9) | 1.56 (0.94 to 2.59) | 0.088 | 55 (25%) | 72.0 (64.7 to 79.2) | 2.20 (1.30 to 3.71) | 0.003 |
| II | 49 | 15 (31%) | 62.1 (45.4 to 78.8) | 2.15 (1.12 to 4.15) | 0.022 | 14 (29%) | 66.4 (50.2 to 82.6) | 2.42 (1.21 to 4.84) | 0.012 |
| Age of diagnosis | 404 | 83 (21%) | 75.3 (70.3 to 80.3) | 1.011 (0.989 to 1.034) | 0.33 | 88 (22%) | 76.3 (71.3 to 81.2) | 1.07 (1.04 to 1.09) | <0.001 |
C, chemotherapy; EBRT, external beam radiation therapy; OBS, observation; OS, overall survival; PFS, progression-free survival; VBT, vaginal brachytherapy.